Treatment for Community-Acquired Pneumonia in Hospitalized Patients with Penicillin Allergy

Non-ICU Hospitalized Patients (Non-Severe CAP)

The Infectious Diseases Society of America recommends respiratory fluoroquinolone monotherapy, such as levofloxacin 750 mg daily or moxifloxacin 400 mg daily, for non-severe cases of community-acquired pneumonia in hospitalized patients with penicillin allergy, with strong recommendation and Level I evidence 1
The American Thoracic Society suggests that levofloxacin 750 mg IV/oral once daily or moxifloxacin 400 mg IV/oral once daily can be used as primary treatment for non-severe CAP in patients with penicillin allergy 1
Aztreonam 2 g IV every 8 hours plus azithromycin 500 mg IV/oral daily can be used as an alternative option for non-severe CAP in patients with penicillin allergy, as it substitutes aztreonam for β-lactam coverage without cross-reactivity risk 2

The Infectious Diseases Society of America recommends mandatory combination therapy with a respiratory fluoroquinolone, such as levofloxacin 750 mg IV daily or moxifloxacin 400 mg IV daily, plus aztreonam 2 g IV every 8 hours, for severe CAP requiring ICU admission in patients with penicillin allergy 1
This regimen provides broad-spectrum coverage for severe pneumonia while avoiding all β-lactam exposure 1

For suspected MRSA, the Infectious Diseases Society of America recommends adding vancomycin 15 mg/kg IV every 8-12 hours or linezolid 600 mg IV every 12 hours to the base regimen 1
For suspected Pseudomonas aeruginosa, the American Thoracic Society suggests using an antipseudomonal fluoroquinolone, such as levofloxacin 750 mg or ciprofloxacin, plus aztreonam plus aminoglycoside 1

The Infectious Diseases Society of America recommends a minimum treatment duration of 5 days with clinical stability criteria met, including being afebrile for 48-72 hours and having no more than 1 sign of clinical instability 1
For confirmed Legionella, Staphylococcus aureus, or gram-negative enteric bacilli, the American Thoracic Society suggests extending treatment to 14-21 days 3

The Infectious Diseases Society of America recommends administering the first antibiotic dose in the emergency department before hospital admission 2
The American Thoracic Society suggests avoiding macrolide monotherapy in penicillin-allergic patients, as it lacks adequate coverage for typical bacterial pathogens and resistance rates exceed 25% in many areas 3

The British Thoracic Society recommends initial monitoring of temperature, respiratory rate, pulse, blood pressure, mental status, oxygen saturation, and inspired oxygen concentration at least twice daily 4
The British Thoracic Society suggests maintaining PaO₂ >8 kPa and SaO₂ >92% with oxygen therapy 4